MedElevator Войти в исследования
← Поиск публикаций
Nature · 2022

Defining the risk of SARS-CoV-2 variants on immune protection.

СтатьяОбзорПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПоддержка правительства СШАResearch Support, N.I.H., IntramuralНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

DeGrace Marciela M, Ghedin Elodie, Frieman Matthew B, Krammer Florian, Grifoni Alba, Alisoltani Arghavan, Alter Galit, Amara Rama R, Baric Ralph S, Barouch Dan H, Bloom Jesse D, Bloyet Louis-Marie, Bonenfant Gaston, Boon Adrianus C M, Boritz Eli A, Bratt Debbie L, Bricker Traci L, Brown Liliana, Buchser William J, Carreño Juan Manuel, Cohen-Lavi Liel, Darling Tamarand L, Davis-Gardner Meredith E, Dearlove Bethany L, Di Han, Dittmann Meike, Doria-Rose Nicole A, Douek Daniel C, Drosten Christian, Edara Venkata-Viswanadh, Ellebedy Ali, Fabrizio Thomas P, Ferrari Guido, Fischer Will M, Florence William C, Fouchier Ron A M, Franks John, García-Sastre Adolfo, Godzik Adam, Gonzalez-Reiche Ana Silvia, Gordon Aubree, Haagmans Bart L, Halfmann Peter J, Ho David D, Holbrook Michael R, Huang Yaoxing, James Sarah L, Jaroszewski Lukasz, Jeevan Trushar, Johnson Robert M, Jones Terry C, Joshi Astha, Kawaoka Yoshihiro, Kercher Lisa, Koopmans Marion P G, Korber Bette, Koren Eilay, Koup Richard A, LeGresley Eric B, Lemieux Jacob E, Liebeskind Mariel J, Liu Zhuoming, Livingston Brandi, Logue James P, Luo Yang, McDermott Adrian B, McElrath Margaret J, Meliopoulos Victoria A, Menachery Vineet D, Montefiori David C, Mühlemann Barbara, Munster Vincent J, Munt Jenny E, Nair Manoj S, Netzl Antonia, Niewiadomska Anna M, O'Dell Sijy, Pekosz Andrew, Perlman Stanley, Pontelli Marjorie C, Rockx Barry, Rolland Morgane, Rothlauf Paul W, Sacharen Sinai, Scheuermann Richard H, Schmidt Stephen D, Schotsaert Michael, Schultz-Cherry Stacey, Seder Robert A, Sedova Mayya, Sette Alessandro, Shabman Reed S, Shen Xiaoying, Shi Pei-Yong, Shukla Maulik, Simon Viviana, Stumpf Spencer, Sullivan Nancy J, Thackray Larissa B, Theiler James, Thomas Paul G, Trifkovic Sanja, Türeli Sina, Turner Samuel A, Vakaki Maria A, van Bakel Harm, VanBlargan Laura A, Vincent Leah R, Wallace Zachary S, Wang Li, Wang Maple, Wang Pengfei, Wang Wei, Weaver Scott C, Webby Richard J, Weiss Carol D, Wentworth David E, Weston Stuart M, Whelan Sean P J, Whitener Bradley M, Wilks Samuel H, Xie Xuping, Ying Baoling, Yoon Hyejin, Zhou Bin, Hertz Tomer, Smith Derek J, Diamond Michael S, Post Diane J, Suthar Mehul S

Аннотация

The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants that could potentially affect the transmission, virulence, and resistance to infection- and vaccine-induced immunity. The SAVE programme is a critical data-generating component of the US Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines and therapeutics, and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models and notable findings facilitated by this collaborative approach and identify future challenges. This programme is a template for the response to rapidly evolving pathogens with pandemic potential by monitoring viral evolution in the human population to identify variants that could reduce the effectiveness of countermeasures.

Предметные рубрики MeSH

AnimalsBiological EvolutionCOVID-19COVID-19 VaccinesHumansNational Institute of Allergy and Infectious Diseases (U.S.)PandemicsPharmacogenomic VariantsSARS-CoV-2United StatesVirulence